Wire · operational-macro
Pfizer Nets Another FDA Approval for Talzenna, Xtandi in Prostate Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
The FDA approved Pfizer's Talzenna (talazoparib) combined with Xtandi (enzalutamide) for treating metastatic prostate cancer patients with homologous recombination repair gene mutations who are androgen pathway modulation-naïve or sensitive.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it.
◆ ◆ The Wire takeaway
You gain access to a newly cleared treatment route for prostate cancer targeting HRR mutations, opening patient cohorts previously less accessible. Test providers and therapy developers can now align offerings with this FDA clearance to accelerate market adoption.
◆ Coverage
4 sources · 26 Oct 2026
◆ Related on Wire
◆ Topics